Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 7/20 | 0.62 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.48 |
| ▸ | GPBAR1 | Q8TDU6 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31301616 | 0.95 | KMO (0.57) | KMOMAP4K4GPBAR1MEN1MAPT | |
| SCHEMBL31301472 | 0.95 | KMO (0.57) | KMOMAP4K4GPBAR1MEN1MAPT | |
| SCHEMBL31301337 | 0.93 | KMO (0.54) | KMOMAP4K4GPBAR1MEN1MAPT | |
| SCHEMBL31301385 | 0.92 | KMO (0.53) | KMOMAP4K4GPBAR1MEN1MAPT | |
| SCHEMBL31301462 | 0.91 | GPBAR1 (0.53) | KMOMAP4K4GPBAR1MEN1KMT2A | |
| SCHEMBL31301465 | 0.87 | HSD17B1 (0.49) | KMOGPBAR1MEN1KMT2AGRM1 | |
| SCHEMBL31301563 | 0.78 | MAP4K4 (0.50) | KMOMAP4K4GPBAR1MAPTKMT2A | |
| SCHEMBL31301438 | 0.77 | KMO (1.00) | KMOMAP4K4MEN1MAPTKMT2A | |
| SCHEMBL31301430 | 0.76 | GPBAR1 (0.50) | GPBAR1NPC1RAB9A | |
| SCHEMBL25002898 | 0.75 | KMO (0.68) | KMOMAP4K4MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727549-A2 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | University of Georgia Research Foundation, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260097046-A1 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | UNIV GEORGIA (US) | 2026-04-09 | — | — | US | disclosed |
| WO-2024258900-A2 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097046-A1 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | SUB1, PFN1, HCCS | KMO 2781/4885MAP4K4 4387/4885GPBAR1 803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.